P23-Development of Korean Guideline Instrument
for evaluation Namsoon Kim, MD (Presenter) (Donggul, Gyeongju, Gyeongsangbuk-Do, South Korea); Sooyoung Kim, PhD (Hallym University, Medical College, Seoul, South Korea) PRIMARY TRACK: Guideline development SECONDARY TRACK: Guideline appraisal BACKGROUND (INTRODUCTION): In Korea, many guidelines have been developed by using foreign studies and applying adaptation process. The purpose of our study is to develop guideline evaluation instruments that will cover both de novo and adaptation process and be more appropriate for Korean context. LEARNING OBJECTIVES (TRAINING GOALS): 1. Identify different methods used that can improve guideline development and quality. 2. Understand how technological tools can be incorporated to enhance guideline development.
METHODS:
We reviewed AGREE I, AGREE II, and other guideline evaluation instruments. Scope, items, and scale were selected through multistage consensus process. We also did field testing and refinement procedures. Finally, we evaluated several Korean guidelines and analyzed data for reliability and validity. RESULTS: We selected 23 items for de novo process through the first consensus meeting. Now we are preparing the next consensus meeting for adaptation process. After we selected items and scale, we will choose 20 appraisers and evaluate guidelines developed in 5 recent years. Analysis for reliability and sensitivity will be done.
DISCUSSION (CONCLUSION):
This is the first time a guideline evaluation instrument covering both de novo and adaptation process has been developed. We hope this instru- 
LEARNING OBJECTIVES (TRAINING GOALS):
1. Assess the quality of existing guidelines regarding pharmacologic treatment of rheumatoid arthritis. 2. Assess the applicability of the AGREE instrument for the appraisal of consensus statements. 3. Improve search strategies for identifying clinical practice guidelines and consensus statements for guideline adaptation.
METHODS:
We performed a systematic search for CPG and CS in RA published between January 2000 and July 2009 in MEDLINE, EMBASE, and CINAHL databases and the grey literature. Guideline quality was assessed by two raters using the Appraisal of Guidelines Research & Evaluation (AGREE) Instrument. AGREE consists of 23 questions across six domains: scope and purpose, stakeholder involvement, rigor of development, clarity/presentation, application/editorial independence, and a single-item qualitative overall assessment of "Recommend (R)," "Recommend with Provisos (RWP)," and "Would Not Recommend (WNR)." Inter-rater reliability was assessed using ICC and Kappa statistics, and a descriptive analysis of the quality of CPG and CS was performed. RESULTS: Inter-rater reliability was excellent for all AGREE domain scores (ICC ranging from 0.74 to 0.93) and for the overall assessment (Kappa ϭ 1). CPG had higher overall quality scores than CS: R (CPG: 12/33 [36%] vs. CS: 0/24 [0%]), RWP (CPG: 17/33 [52%] vs. CS: 17/24 [71%]) and WNR (CPG: 4/33 [12%] vs. CS: 7/24 [29%]). Both CPG and CS scored highest for "scope and purpose" and "clarity and presentation" and lowest for "applicability" and "editorial independence." Only 16/33 (48.5%) CPG vs. 23/24 (96%) CS were published in journals.
DISCUSSION (CONCLUSION):
The quality of published guidelines in RA is variable, with few guidelines rating as high quality. CS were rated as lower than CPG. Less than half of CPG are published in journals, suggesting that broader search strategies for identifying CPG are warranted. TARGET AUDIENCE(S): 1. Clinical researcher 2. Evidence synthesizer, developer of systematic reviews or meta-analyses 3. Guideline developer 4. Guideline implementer 5. Developer of guideline-based products 6. Quality improvement manager/facilitator 7. Health care policy analyst/policy-maker 8. Medical providers and executives 9. Consumers and patients representatives
